No abstract

BackgroundAnxiety disorder, one of the highly disabling, prevalent and common mental disorders, is known to be more prevalent in persons with type 2 diabetes mellitus (T2DM) than the general population, and the comorbid presence of anxiety disorders is known to have an impact on the diabetes outcome and the quality of life. However, the information on the type of anxiety disorder and its prevalence in persons with T2DM is limited.AimsTo assess the prevalence and correlates of anxiety disorder in people with type 2 diabetes in different countries.MethodsPeople aged 18–65 years with diabetes and treated in outpatient settings were recruited in 15 countries and underwent a psychiatric interview with the Mini-International Neuropsychiatric Interview. Demographic and medical record data were collected.ResultsA total of 3170 people with type 2 diabetes (56.2% women; with mean (SD) duration of diabetes 10.01 (7.0) years) participated. The overall prevalence of anxiety disorders in type 2 diabetic persons was 18%; however, 2.8% of the study population had more than one type of anxiety disorder. The most prevalent anxiety disorders were generalised anxiety disorder (8.1%) and panic disorder (5.1%). Female gender, presence of diabetic complications, longer duration of diabetes and poorer glycaemic control (HbA1c levels) were significantly associated with comorbid anxiety disorder. A higher prevalence of anxiety disorders was observed in Ukraine, Saudi Arabia and Argentina with a lower prevalence in Bangladesh and India.ConclusionsOur international study shows that people with type 2 diabetes have a high prevalence of anxiety disorders, especially women, those with diabetic complications, those with a longer duration of diabetes and poorer glycaemic control. Early identification and appropriate timely care of psychiatric problems of people with type 2 diabetes is warranted.

No abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare condition affecting between 1 in 1,000 to 1 in 10,000 patients after exposure to associated drugs. [1] It is a life-threatening condition with a mortality rate of about 10%, which necessitates early identification and treatment. [2] We describe a case of DRESS syndrome secondary to the use of chlorpromazine in a female with paranoid schizophrenia, the diagnostic challenge encountered, and the successful treatment of the condition with corticosteroids. Financial support and sponsorship Nil.

No abstract